Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) versus chemo (C)

被引：0
|
作者：
Moehler, M. [1 ]
Wyrwicz, L. [2 ]
Chen, C. [3 ]
Davenport, E. [4 ]
Wang, J. [4 ]
Nathani, R. [3 ]
Kondo, K. [3 ]
Elimova, E. [5 ]
机构：
[1] Johannes Gutenberg Univ Mainz, Mainz, Germany
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] RTI Int, Res Triangle Pk, NC USA
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-10
引用
收藏
页码：S185 / S185
页数：1
相关论文
共 50 条
  • [1] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Chen, Clara
    Blum, Steven Michael
    Davenport, Eric
    Wang, Jinyi
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Moehler, M.
    Elimova, E.
    Blum, S., I
    Xiao, H.
    Davenport, E.
    Wang, J.
    Hunter, S.
    Li, M.
    Kondo, K.
    Wyrwicz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
  • [3] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Blum, Steven I.
    Xiao, Hong
    Li, Mingshun
    Kondo, Kaoru
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [4] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.
    Wyrwicz, Lucjan
    Elimova, Elena
    Blum, Steven I.
    Xiao, Hong
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Li, Mingshun
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
    Moehler, Markus
    Xiao, Hong
    Blum, Steven I.
    Elimova, Elena
    Cella, David
    Shitara, Kohei
    Ajani, Jaffer A.
    Janjigian, Yelena Y.
    Garrido, Marcelo
    Shen, Lin
    Yamaguchi, Kensei
    Liu, Tianshu
    Schenker, Michael
    Kowalyszyn, Ruben
    Bragagnoli, Arinilda Campos
    Bruges, Ricardo
    Montesarchio, Vincenzo
    Pazo-Cid, Roberto
    Hunter, Shannon
    Davenport, Eric
    Wang, Jinyi
    Kondo, Kaoru
    Li, Mingshun
    Wyrwicz, Lucjan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (35) : 5388 - +
  • [6] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    CANCER RESEARCH, 2022, 82 (12)
  • [8] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Ruihua
    Guo, Weijian
    Qin, Shukui
    Yang, Nong
    Lu, Jianwei
    Shitara, Kohei
    Lei, Ming
    Li, Mingshun
    Bao, Nicole
    Chen, Tian
    Liu, Tianshu
    CANCER RESEARCH, 2021, 81 (13)
  • [9] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Janjigian, Y. Y.
    Ajani, J. A.
    Moehler, M.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Li, M.
    Poulart, V.
    Lei, M.
    Kondo, K.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
  • [10] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
    Moehler, Markus H.
    Shitara, Kohei
    Garrido, Marcelo
    Salman, Pamela
    Shen, Lin
    Wyrwicz, Lucjan
    Yamaguchi, Kensei
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Schenker, Michael
    Yanez, Patricio Eduardo
    Tehfe, Mustapha
    Li, Mingshun
    Cullen, Dana
    Memaj, Arteid
    Lei, Ming
    Xiao, Hong
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345